Your browser doesn't support javascript.
loading
[Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir®), a therapeutic agent for Clostridioides (Clostridium) difficile infection].
Takeda, Shinobu; Miki, Takashi.
Affiliation
  • Takeda S; Candidate Discovery Science Labs, Drug Discovery Research, Astellas Pharma Inc.
  • Miki T; Japan-Asia Clinical Development II, Development, Astellas Pharma Inc.
Nihon Yakurigaku Zasshi ; 154(4): 217-229, 2019.
Article in Ja | MEDLINE | ID: mdl-31597902
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Plantas_medicinales Main subject: Clostridioides difficile / Clostridium Infections / Fidaxomicin / Anti-Bacterial Agents Type of study: Prognostic_studies Country/Region as subject: Asia Language: Ja Journal: Nihon Yakurigaku Zasshi Year: 2019 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Plantas_medicinales Main subject: Clostridioides difficile / Clostridium Infections / Fidaxomicin / Anti-Bacterial Agents Type of study: Prognostic_studies Country/Region as subject: Asia Language: Ja Journal: Nihon Yakurigaku Zasshi Year: 2019 Type: Article